Company intelligence / Profile preview

AUM BioTech

Ownership: Private
Development stage: Commercial

Overview

Provides validated self-delivering antisense technologies enabling robust gene silencing in vitro and in vivo without transfection reagents. Widely adopted by academic and industry researchers globally for target validation and mechanistic studies across multiple biomedical fields.[2][3][4]

Therapeutic areas: OncologyImmunologyOtherNeurologyInfectious Diseases
Modalities: Antisense oligonucleotides (ASOs)Self-delivering antisense oligonucleotides (sdASO™)FANA ASOs (2'-deoxy-2'-fluoro-arabinonucleic acid antisense oligos)Exon skipping ASOs[4]Blocker oligos[4]Transfection-free gene silencing reagents[2][3][4]
Industry: Non-Drug Biotech

Drug pipeline

7 assets

AUMsilence

Commercial

Indications: Research use only

6 more assets in the full pipeline.

Partnerships

A joint initiative with AUM LifeTech (“Knockdown Coronavirus” program); no major pharma partnerships disclosed.[3]

Beyond the preview

Go deeper on AUM BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUM BioTech.